Century Therapeutics, Inc. (IPSC)
| Market Cap | 336.80M +692.6% |
| Revenue (ttm) | n/a +1,556.8% |
| Net Income | -109.79M |
| EPS | -0.77 |
| Shares Out | 181.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,369,353 |
| Open | 1.880 |
| Previous Close | 1.880 |
| Day's Range | 1.815 - 1.880 |
| 52-Week Range | 0.435 - 3.040 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | 4.75 (+155.38%) |
| Earnings Date | Aug 12, 2026 |
About IPSC
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoim... [Read more]
Financial Performance
In 2025, Century Therapeutics's revenue was $109.16 million, an increase of 1556.76% compared to the previous year's $6.59 million. Losses were -$9.58 million, -92.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IPSC stock is "Buy." The 12-month stock price target is $4.75, which is an increase of 155.38% from the latest price.
News
Century Therapeutics Appoints Joseph Truitt to Board of Directors
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies fo...
Century Therapeutics reports Q2 EPS (17c), consensus (12c)
“We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale,” said Br...
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 pre...
Century Therapeutics Quarterly report: Q2 2026
Century Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Century Therapeutics Earnings release: Q2 2026
Century Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power plants across the U.S., has a new name as it enters a new chapter. Effective today, IPSC officially b...
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics presents new preclinical data for CNTY-813
Century Therapeutics (IPSC) announced the presentation of new preclinical data for its stem cell-derived islet replacement therapy, CNTY-813, at the American Diabetes Association Scientific Sessions. ...
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for...
Century Therapeutics initiated with an Outperform at Mizuho
Mizuho initiated coverage of Century Therapeutics (IPSC) with an Outperform rating and $8 price target The company has a potentially curative cell therapy for type 1 diabetes, the analyst tells…
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Century Therapeutics reports Q1 EPS (11c), consensus (17c)
“We are executing our pipeline with discipline to deliver an iPSC-derived islet replacement therapy to patients. The progress of CNTY-813 highlights what Century can achieve pairing our Allo-Evasion e...
Century Therapeutics Reports First Quarter Financial Results and Business Updates
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for ...
Century Therapeutics Quarterly report: Q1 2026
Century Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Century Therapeutics Earnings release: Q1 2026
Century Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet...
Century Therapeutics Proxy statement: Proxy filing
Century Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Century Therapeutics Proxy statement: Proxy filing
Century Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Century Therapeutics price target raised to $5 from $2 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Century Therapeutics (IPSC) to $5 from $2 and keeps a Buy rating on the shares. Vertex has shown stem-cell…
Century Therapeutics Proxy statement: Proxy filing
Century Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Century Therapeutics reports FY25 EPS (14c), consensus (17c)
Reports FY25 revenue $109.164M, consensus $109.17M. “Century entered 2026 with strong momentum, fueled by the successful completion of our $135 million private placement and continued focus on advanci...
Century Therapeutics Earnings release: Q4 2025
Century Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Century Therapeutics Annual report: Q4 2025
Century Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Century Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted its iPSC platform to focus on beta islet cell therapy for type 1 diabetes, targeting a large unmet need with a holistic immune evasion strategy and scalable manufacturing innovations. IND submission is planned for late 2025, with initial clinical data expected in 2027.
Century Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Two lead programs, CNTY-813 for Type 1 Diabetes and CNTY-308 for autoimmune diseases, are advancing toward clinical trials in 2024, both leveraging advanced immune evasion technology. The company aims for a functional cure in diabetes and broad application of iPSC-derived therapies, with a cash runway to Q1 2029.